Welcome to our dedicated page for GlucoTrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on GlucoTrack stock.
GlucoTrack, Inc. develops medical technology for people with diabetes, centered on a long-term, fully implantable continuous blood glucose monitoring system. Company news commonly covers the CBGM platform, FDA Investigational Device Exemption activity, preclinical and clinical-study disclosures, and peer-reviewed publications on sensor stability, accuracy, and implantable device performance.
Updates also include intellectual-property developments for proprietary sensor chemistry, intravascular lead design, and low-power electronics, along with financial results, research and development spending, capital actions, and conference presentations tied to the company’s diabetes device strategy.
Glucotrack (GCTK) entered into definitive agreements for approximately $11.5 million in aggregate principal amount of convertible notes. The financing includes about $4.5 million of new cash investment and approximately $4.5 million of existing notes being rolled over, with the total principal amount reflecting a 22% original issue discount. The notes are initially convertible at $3.12 per share, and participating investors will also receive warrants exercisable at $7.50 per share. Dawson James Securities acted as sole placement agent. Glucotrack operates the Lōkahi platform and develops investigational long-term implantable continuous blood glucose monitoring technology.
Lōkahi Therapeutics (GCTK) has expanded its ai² platform into three business divisions: ai² Pipeline, ai² Talent, and ai² Accelerator, aiming to create new revenue-generating opportunities while supporting its therapeutic development strategy.
Since launching about one year ago, ai² has grown from one university collaboration to 13 participating universities and has identified and evaluated more than 45 therapeutic assets, with several now in active business diligence. The new structure is intended to provide Lōkahi with a sustainable source of development opportunities and attract external interest from biotechnology companies, academic institutions, and strategic partners through potential partnerships, licensing, workforce development, and technology-driven data solutions.
Glucotrack (GCTK), through its subsidiary Lōkahi Therapeutics, announced a new collaboration with San Diego State University’s Fowler College of Business to expand the ai² Futures Lab asset origination network.
The partnership is intended to enhance Lōkahi’s ability to identify and evaluate overlooked or deprioritized therapeutic assets while providing SDSU students with practical experience in biopharmaceutical business challenges. In its first year, the ai² Futures Lab engaged 64 students and identified more than 45 potential assets, several of which entered active pipeline discussions. SDSU participants will focus on asset identification, evaluation, and strategic assessment, generating recommendations that may support partnership, licensing, or acquisition opportunities. Lōkahi positions the ai² Futures Lab as a scalable, capital-efficient model that can later expand into specialized tracks aligned with its Discover, Advance, Monetize framework.
Glucotrack (Nasdaq: GCTK) will implement a 1-for-15 reverse stock split of its common stock, effective at the opening of trading on August 31, 2026. The stock will continue trading on Nasdaq under “GCTK” with new CUSIP 45824Q887.
The split will reduce outstanding common shares from 11,972,157 to approximately 798,144, combining every 15 shares into one. No fractional shares will be issued; holdings will be rounded up to the next whole share. The move is intended to help Glucotrack meet Nasdaq’s $1.00 minimum bid price requirement and broaden institutional investor appeal. The company must maintain at least a $1.00 closing bid price on each trading day through November 9, 2026 to preserve its Nasdaq listing.
Glucotrack (NASDAQ: GCTK) announced that subsidiary Lōkahi Therapeutics has initiated its first GMP manufacturing campaign for LT-100, a pure honeybee venom biologic and lead candidate for osteoarthritis knee pain.
The campaign is intended to supply clinical trial material for once-weekly, single subcutaneous injections, replacing the 15 intradermal injections per treatment used in prior efficacy trials. According to the company, successful completion of manufacturing, quality assurance, remaining clinical preparations and regulatory review could allow enrollment of the first patient later this year, supporting upcoming clinical and regulatory milestones.
Lōkahi Therapeutics (Nasdaq: GCTK), a subsidiary of Glucotrack, announced the continued participation of the University of Georgia’s Student Industry Fellows Program in its ai² Futures Lab, expanding a nationwide academic network that helps identify and evaluate overlooked or strategically deprioritized therapeutic assets in a capital‑efficient way.
According to Lōkahi Therapeutics, the ai² Futures Lab engaged 64 students in its first year and surfaced more than 45 potential acquisition assets, with several progressing into active pipeline discussions. The renewed collaboration will keep students focused on asset identification, evaluation and strategic recommendations that may inform Lōkahi’s diligence, partnership, licensing or acquisition decisions.
Glucotrack (Nasdaq: GCTK) reported that a Nasdaq Hearings Panel has granted its request for continued listing on The Nasdaq Stock Market, subject to certain conditions. The Panel confirmed that Glucotrack has regained compliance with Nasdaq’s stockholders’ equity requirement, marking a key milestone in the company’s strategic transformation.
Management highlighted recent actions to strengthen the company, improve its financial foundation and pursue long-term growth and shareholder value, while continuing to work toward full compliance with all applicable Nasdaq standards. Glucotrack operates the Lōkahi Therapeutics platform and is developing an investigational long-term implantable continuous blood glucose monitoring system.
Glucotrack (NASDAQ: GCTK) announced definitive agreements for approximately $5.5 million in financing from institutional investors. The package includes a $2.0 million equity financing priced at $0.75 per unit, described as a premium to the market, and a $3.5 million follow-on investment in the form of convertible debt.
Each equity unit consists of one share of common stock (or equivalent) and one five-year warrant with an exercise price of $1.50 per share. According to Glucotrack, the transaction strengthens its balance sheet and provides additional growth capital. E.F. Hutton & Co. acted as exclusive advisor to Lōkahi Therapeutics, a Glucotrack subsidiary.
Glucotrack (NASDAQ: GCTK) reported first-year results and expansion of the ai² Futures Lab™ operated by its wholly owned subsidiary, Lōkahi Therapeutics. On a budget of about $33,000, the program identified more than 45 potential therapeutic assets and advanced five into active company discussions. These assets collectively represent over $500 million in prior biopharmaceutical investment and include programs with human clinical data, positive efficacy signals, and remaining exclusivity.
For the 2026–2027 academic year, ai² Futures Lab™ is expanding from six to 12 university collaborations while maintaining 100% retention of inaugural partners and has generated two full-time hires and 20+ consulting engagements. The platform leverages student teams working in 8–10 week engagements across clinical, commercial, regulatory, IP, financial, and strategic workstreams to provide a capital-efficient source of late-stage asset opportunities within Lōkahi’s Discover, Advance, Monetize model.
Glucotrack (NASDAQ: GCTK) released a corrected update on the ai² Futures Lab™ run through its subsidiary Lōkahi Therapeutics. In its first year, the Lab identified more than 45 therapeutic assets on an approximately $33,000 budget and moved five into active company discussions. These opportunities represent over $500 million in prior biopharmaceutical investment and include assets with human clinical data, positive efficacy signals, and meaningful remaining exclusivity.
The ai² Futures Lab™ is expanding from six to 13 university partners for the 2026–2027 academic year with 100% retention of inaugural collaborators. According to Lōkahi, the program functions as a capital‑efficient, distributed asset‑origination engine and has also generated two full‑time hires and more than 20 consulting engagements.